Name | Title | Contact Details |
---|---|---|
Anthony Ambrozie |
Senior Vice President and Chief Digital Officer | Profile |
PWNHealth is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. Our model enables safe and easy access to diagnostic testing, ensuring clinical validity, utility, quality consumer education, access to clinicians, and the ability to implement national programs seamlessly. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets. Through integration with more than 80 CLIA-certified labs and support of over 3,000 test types, we are shaping a new paradigm in healthcare, servicing all 50 states and Puerto Rico. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWNHealth is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF).
Patterson Medical is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lifemark Health Group is a diversified healthcare company in business since 1998 and has grown by acquisition over the past 13 years to include over 200 facilities across Canada.
Accent Urgent Care and After Hours Pediatrics is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.